Literature DB >> 16951312

Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation.

Philippe Grimbert1, Salim Bouguermouh, Nobuyasu Baba, Toshiharu Nakajima, Zoulfia Allakhverdi, Deborah Braun, Hirohisa Saito, Manuel Rubio, Guy Delespesse, Marika Sarfati.   

Abstract

Thymus-derived CD4+ CD25+ T regulatory cells (Tregs) are essential for the maintenance of self-tolerance. What critical factors and conditions are required for the extra-thymic development of Tregs remains an important question. In this study, we show that the anti-inflammatory extracellular matrix protein, thrombospondin-1, promoted the generation of human peripheral regulatory T cells through the ligation of one of its receptor, CD47. CD47 stimulation by mAb or a thrombospondin-1 peptide induced naive or memory CD4+ CD25- T cells to become suppressive. The latter expressed increased amounts of CTLA-4, OX40, GITR, and Foxp3 and inhibited autologous Th0, Th1, and Th2 cells. Their regulatory activity was contact dependent, TGF-beta independent, and partially circumvented by IL-2. This previously unknown mechanism to induce human peripheral Tregs in response to inflammation may participate to the limitation of collateral damage induced by exacerbated responses to self or foreign Ags and thus be relevant for therapeutic intervention in autoimmune diseases and transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951312     DOI: 10.4049/jimmunol.177.6.3534

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

1.  Antigen-induced regulation of T-cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors.

Authors:  Sten-Erik Bergström; Mehmet Uzunel; Toomas Talme; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

4.  Thrombospondin-1 (TSP1)-producing B cells restore antigen (Ag)-specific immune tolerance in an allergic environment.

Authors:  Gui Yang; Xiao-Rui Geng; Zhi-Qiang Liu; Jiang-Qi Liu; Xiao-Yu Liu; Ling-Zhi Xu; Huan-Ping Zhang; Ying-Xue Sun; Zhi-Gang Liu; Ping-Chang Yang
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

Review 5.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 6.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 7.  Review of the activation of TGF-beta in immunity.

Authors:  Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2008-09-25       Impact factor: 4.962

Review 8.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  A novel cancer therapeutic using thrombospondin 1 in dendritic cells.

Authors:  Tzu-Yang Weng; Shih-Shien Huang; Meng-Chi Yen; Chi-Chen Lin; Yi-Ling Chen; Chiu-Mei Lin; Wei-Ching Chen; Chih-Yang Wang; Jang-Yang Chang; Ming-Derg Lai
Journal:  Mol Ther       Date:  2013-10-15       Impact factor: 11.454

Review 10.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.